TY - JOUR
T1 - Novel effects of sarcopenic osteoarthritis on metabolic syndrome, insulin resistance, osteoporosis, and bone fracture
T2 - The national survey
AU - Chung, S. M.
AU - Hyun, M. H.
AU - Lee, E.
AU - Seo, H. S.
N1 - Funding Information:
This work was supported by a grant from the Korea Institute of Science and Technology Institutional Program (Project No. 2E24080), a grant from the Korea University-Korea Institute of Science and Technology (KU-KIST) Graduate School of Converging Science and Technology (R1307921).
Publisher Copyright:
© International Osteoporosis Foundation and National Osteoporosis Foundation 2016.
PY - 2016/5/13
Y1 - 2016/5/13
N2 - This study compared the effects sarcopenic osteoarthritis on metabolic syndrome, insulin resistance, osteoporosis, and bone fracture. By using national survey data, we suggest that the relationship between sarcopenia and metabolic syndrome or insulin resistance is potentiated by the severity of osteoarthritis and is independent of body weight. Introduction Sarcopenia and osteoarthritis are known risk factors for metabolic syndrome. However, their combined effects on metabolic syndrome, insulin resistance and osteoporosis remain uncertain. Methods We used data from the fifth Korean National Health and Nutrition Examination Survey using a total of 3158 adults (age >50 years). Sarcopenia was defined as a skeletal muscle index score (appendicular skeletal muscle mass/body weight) within the fifth percentile of sex-matched younger reference participants. Radiographic knee osteoarthritis was defined as a Kellgren-Lawrence (K-L) grade of 2 or greater. Metabolic syndrome was diagnosed using the National Cholesterol Education Program criteria. Insulin resistance was evaluated using the homeostasis model assessment-estimated insulin resistance index (HOMA-IR). Osteoporosis was defined using the World Health Organization T-score criteria. Results In multivariable logistic regression analysis, the sarcopenic osteoarthritis group had a higher odds ratio (OR) for metabolic syndrome (OR=11.00, 95%confidential interval (CI) =2.12–56.99, p=0.013) than the non-sarcopenic osteoarthritis (OR = 1.02, 95% CI = 0.65–1.62, p = 0.972) and sarcopenic non-osteoarthritis groups (OR = 7.15, 95% CI=1.57–32.53, p=0.027). Similarly, sarcopenic osteoarthritis had a greater OR of highest HOMA-IR quartiles (OR=8.19, 95%CI=2.03–33.05, p=0.003) than the other groups.Overall, the association between the K-L grade and body mass index was significant; however, this significance was lower in individuals with sarcopenia and was lost in those with sarcopenic osteoarthritis. Additionally, osteoporosis and bone fracture were not associated to sarcopenic osteoarthritis (p>0.05). Conclusions These results suggest that the relationship between sarcopenia and metabolic syndrome or insulin resistance is potentiated by the severity of osteoarthritis and is independent of body weight.
AB - This study compared the effects sarcopenic osteoarthritis on metabolic syndrome, insulin resistance, osteoporosis, and bone fracture. By using national survey data, we suggest that the relationship between sarcopenia and metabolic syndrome or insulin resistance is potentiated by the severity of osteoarthritis and is independent of body weight. Introduction Sarcopenia and osteoarthritis are known risk factors for metabolic syndrome. However, their combined effects on metabolic syndrome, insulin resistance and osteoporosis remain uncertain. Methods We used data from the fifth Korean National Health and Nutrition Examination Survey using a total of 3158 adults (age >50 years). Sarcopenia was defined as a skeletal muscle index score (appendicular skeletal muscle mass/body weight) within the fifth percentile of sex-matched younger reference participants. Radiographic knee osteoarthritis was defined as a Kellgren-Lawrence (K-L) grade of 2 or greater. Metabolic syndrome was diagnosed using the National Cholesterol Education Program criteria. Insulin resistance was evaluated using the homeostasis model assessment-estimated insulin resistance index (HOMA-IR). Osteoporosis was defined using the World Health Organization T-score criteria. Results In multivariable logistic regression analysis, the sarcopenic osteoarthritis group had a higher odds ratio (OR) for metabolic syndrome (OR=11.00, 95%confidential interval (CI) =2.12–56.99, p=0.013) than the non-sarcopenic osteoarthritis (OR = 1.02, 95% CI = 0.65–1.62, p = 0.972) and sarcopenic non-osteoarthritis groups (OR = 7.15, 95% CI=1.57–32.53, p=0.027). Similarly, sarcopenic osteoarthritis had a greater OR of highest HOMA-IR quartiles (OR=8.19, 95%CI=2.03–33.05, p=0.003) than the other groups.Overall, the association between the K-L grade and body mass index was significant; however, this significance was lower in individuals with sarcopenia and was lost in those with sarcopenic osteoarthritis. Additionally, osteoporosis and bone fracture were not associated to sarcopenic osteoarthritis (p>0.05). Conclusions These results suggest that the relationship between sarcopenia and metabolic syndrome or insulin resistance is potentiated by the severity of osteoarthritis and is independent of body weight.
KW - Insulin resistance
KW - Metabolic syndrome
KW - Osteoarthritis
KW - Sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85027931713&partnerID=8YFLogxK
U2 - 10.1007/s00198-016-3548-0
DO - 10.1007/s00198-016-3548-0
M3 - Article
C2 - 27177746
AN - SCOPUS:85027931713
SN - 0937-941X
VL - 27
SP - 2447
EP - 2457
JO - Osteoporosis International
JF - Osteoporosis International
IS - 8
ER -
